CoapTech is an early-stage medical device company aiming to improve medical care delivery for patients young and old around the world. The company seeks to bring a series of breakthrough medical devices to worldwide markets, leveraging a patent-pending, disruptive technology called Coaptive Ultrasound which is owned by the company. Its devices reduce healthcare costs and improve safety, quality, patient experience, and access to services around the globe. Invented by Dr. Tropello, CoapTech delivers a novel platform technology combining magnetic attraction for device placement guidance, and low-cost, point-of-care ultrasound for visual feedback in diagnostic, interventional, and therapeutic procedures. Strong rare-earth magnets are used to manually guide devices placed inside the human body, while real-time, low-cost ultrasound provides visual feedback to the clinician to ensure safety. This platform technology, invented by the company founder, has the potential to disrupt multiple medical procedures, substantially reducing costs while improving safety and patient experience. Their lead use case, selected because of its low risk, clear FDA pathway, and strong commercial viability, is for the insertion of gastrostomy tubes. They have defined the use of Coaptive Ultrasound to perform this novel gastrostomy procedure, as Percutaneous Ultrasound Gastrostomy (PUG). Briefly, PUG is a point-of-care (as opposed to the operating room) procedure for inserting gastrostomy tubes which can be quickly and easily performed by non-surgical providers. It employs readily available medical devices such as ultrasound, feeding tubes, guide wires, and dilators.